Iovance Biotherapeutics Inc (IOVA)
NASDAQ:IOVA
Want to see IOVA full AI Analyst Report?
Earnings Data
Report Date
Aug 06, 2026TBA (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.13Last Year’s EPS
-0.33Same Quarter Last Year
Moderate Buy
Based on 10 Analysts Ratings
Earnings Call Summary
Q1 2026
Earnings Call Date:May 07, 2026|
% Change Since:
|
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum and meaningful operational progress: high single-quarter revenue growth (~45% YoY), robust Amtagvi demand (+38% YoY), tighter Q2/full-year guidance, expanded manufacturing control, R&D cost reductions, extended cash runway into 2028, and encouraging early clinical signals (e.g., 40% ORR in serous endometrial cancer). Near-term headwinds include a one-time facility-related margin hit (Q1 gross margin ~41%), some quarter-to-quarter revenue volatility in Proleukin, continued use of ATM financing, and the usual clinical/regulatory and enrollment execution risks. Overall, the positives—notably accelerating commercial traction, pipeline advances, and improved cost discipline—substantially outweigh the listed challenges.Company Guidance
Strong Top-Line Growth
First quarter revenue of $71 million, an approximately 45% year-over-year increase, driven by strong Amtagvi demand.
Amtagvi Commercial Momentum
Amtagvi revenue of $60 million in Q1, up ~38% year-over-year and the company's second-highest quarterly Amtagvi result; March was the largest month ever for reported Amtagvi revenue.
Tight Q2 and Full-Year Revenue Guidance
Q2 total revenue guidance of $86M–$88M with Amtagvi expected at $79M–$81M (an ~23% increase versus the company's prior highest quarterly revenue); full-year 2026 guidance of $350M–$370M for Amtagvi and Proleukin.
Improving Financial Discipline and Runway Extension
Research and development expense declined for the third consecutive quarter (down 18% versus the prior period and 12% versus the prior quarter); cash and equivalents of ~$319M as of March 31 with expectation to fund operations into 2028.
Manufacturing Control and Capacity Restoration
Completed maintenance upgrades at internal iCTC manufacturing facility; Amtagvi is now exclusively manufactured in-house with a modular facility designed to provide uninterrupted supply and support global scale.
Favorable Unit Economics Signals
Reported gross-to-net impact remains below 2%; Q1 gross margin from cost of sales ~41% despite one-time upgrade costs and management expects margins to trend higher for the remainder of 2026 excluding one-time items.
Clinical and Pipeline Advances
Announced compelling early Phase II data in metastatic serous endometrial cancer with a confirmed objective response rate (ORR) of 40% and 100% disease control rate in first five patients; pursuing FDA engagement for expedited approval.
Broad Registrational and Next-Generation Programs
Progress across registrational trials and next-gen candidates: TILVANCE-301 (frontline melanoma) ongoing; lifileucel Fast Track in previously treated non-squamous NSCLC targeting accelerated approval and potential H2 2027 launch; IOV-SAR-201 (soft tissue sarcoma) enrollment beginning Q3 2026; IOV-5001 IND submitted (Phase I/II expected H2 2026); IOV-3001 and IOV-4001 advancing.
Commercial Reach and Awareness Growth
ATC network expanding (targeting ~110 by year-end) and physician awareness increased from 50% to 70% over the prior six months; first ex-U.S. treatment center authorized in Canada with regulatory progress planned in Australia (H1) and Switzerland (next year).
IOVA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
IOVA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2026 | $4.09 | $3.55 | -13.20% |
Feb 24, 2026 | $2.89 | $3.78 | +30.80% |
Nov 06, 2025 | $1.81 | $2.31 | +27.62% |
Aug 07, 2025 | $2.64 | $2.11 | -20.08% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Iovance Biotherapeutics Inc (IOVA) report earnings?
Iovance Biotherapeutics Inc (IOVA) is schdueled to report earning on Aug 06, 2026, TBA (Confirmed).
What is Iovance Biotherapeutics Inc (IOVA) earnings time?
Iovance Biotherapeutics Inc (IOVA) earnings time is at Aug 06, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is IOVA EPS forecast?
IOVA EPS forecast for the fiscal quarter 2026 (Q2) is -0.13.